L & S Advisors’s United Therapeutics UTHR Stock Holding History

L & S Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-3,000	Closed	-$455K	–	396
2020 Q4	$455K	Buy	+3,000	New	+$394K	0.05%	256

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

L & S Advisors's UTHR Position: Q1 2021 in Review

L & S Advisors sold out of United Therapeutics (UTHR) in Q1 2021, closing a stake of 3,000 shares — an estimated $455K sold.

L & S Advisors first reported a position in UTHR in Q4 2020 and held it in 1 quarter. The position peaked at $455K in Q4 2020. 391 funds tracked by Wall St. Rank hold UTHR as of Q1 2021.

L & S Advisors reported no remaining United Therapeutics position as of Q1 2021 after selling out during the quarter.
L & S Advisors sold 3,000 United Therapeutics shares in Q1 2021, an estimated $455K.
L & S Advisors first reported a position in United Therapeutics in Q4 2020 and held it in 1 quarter.
L & S Advisors's United Therapeutics position peaked at $455K in Q4 2020.
391 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2021.

Based on L & S Advisors's 13F filing for Q1 2021, filed 10 May 2021.